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 Epidemiology of hepatocellular carcinoma
Primary liver cancer is the third-most-common cause of 
cancer death worldwide (1), and hepatocellular carcinoma 
(HCC)  accounts  for  85-90%  of  these  cancers.  Worldwide, 
between 500,000 and one million new HCC cases are diag-
nosed each year, with an age-adjusted annual incidence of 
14.9 per 100,000 in men and 5.5 per 100,000 in women (2, 3). 
More than 80% of the cases occur in East Asia (age-adjusted 
annual incidence 35.2-48.8 per 100,000 in men and 11.6-13.3 
per 100,000 in women) and Sub-Saharan Africa (age-adjust-
ed annual incidence 28.5-39.7 per 100,000 in men and 12.2-
14.6 per 100,000 in women), where hepatitis B virus (HBV) 
infection is endemic. China alone accounts for 55% of all HCC 
patients (1). In contrast, the incidence of HCC is low in North 
and South America, Western and Northern Europe, and Oce-
ania, whereas the median incidence rate of HCC is reported 
in Southern Europe (4). In Iran, the annual incidence of HCC 
is low (0.2 per 100,000, sex- and age-adjusted), possibly be-
cause of the low prevalence of chronic HBV infection (CHB) 
(5, 6).Established risk factors for HCC include chronic infec-
tion with HBV and/or hepatitis C virus (HCV), old age, male 
sex, aflatoxin exposure, alcoholic abuse, diabetes, nonalco-
holic fatty liver disease (NAFLD), hemochromatosis, and vari-
ous host genetic factors. The pattern of major risk factors for 
HCC varies from country to country. In developing countries, 
CHB with or without aflatoxin exposure is responsible for 
the most cases. In developed countries, however, over 90% 
of HCC cases occur in the background of cirrhosis caused by 
chronic HCV infection and alcohol abuse (7, 8). In developed 
countries, people get infected by HBV mainly through sexual 
and other horizontal transmission in adulthood, with more 
than 90% of HBV cleared spontaneously. In developing coun-
tries, in contrast, HBV is usually transmitted from mother 
to child in the perinatal period, and around 90% of infected 
newborns develop CHB (4). CHB is the most important risk 
factor  for  HCC  in  the  world.  It  contributes  to  more  than 
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50% of HCC cases worldwide and 70-80% of HCC cases in the 
high-endemic regions of HBV. The annual incidence of HCC 
among people with CHB ranges from 400-800 per 100,000 
in men and from 120-180 per 100,000 in women. The relative 
risk of HCC among people infected with HBV ranges from 
5-49 in case-control studies and from 7-98 in cohort studies 
(9). Standard HBV vaccination programs decrease the preva-
lence of HCC among the vaccines (10). However, the influence 
of such programs on the incidence rate may not be obvious 
for at least two decades due to the high prevalence of CHB 
and prolonged latency to HCC development (9). Recently, a 
decreasing trend in the incidence of HCC in high-risk areas 
has been reported. The vaccination of all newborns against 
HBV and a shift in diet from corn to rice in some parts of Chi-
na, leading to decreased exposure to aflatoxin, may be the 
major reasons for this decline in incidence (4). In contrast 
to the decline in developing countries, the incidence of HCC 
has been rising in some developed countries, including the 
United States, Italy, the United Kingdom, Canada, and Aus-
tralia (2). This increase is mainly attributed to a greater prev-
alence of HCV infection in these areas and the rising rates 
of obesity and NAFLD (10). Immigration from HBV-endemic 
countries may also contribute to the increasing incidence 
of HCC. The incidence of HCC increases with age, reaching 
a peak among those aged 50-65 in HBV-endemic areas and 
beyond age 65 in non-endemic areas. It was rare for people 
in western countries to develop HCC before 50 years old. But 
in the last two decades, there has been a shift of incidence 
to patients age 40-60 (11), possibly because of an increase in 
HBV-infected individuals in these countries. With the excep-
tion  of  study  populations  with  extremely  low  prevalence 
of HCC, men are 2-4 times more often affected by HCC than 
women,  which  may  be  caused  by  androgenic  hormones 
(12). Host genetic predispositions, such as single nucleotide 
polymorphisms of specific inflammatory factors, have re-
cently been reported to be risk factors for HCC (13-15). This 
may help explain why China accounts for only 1/4-1/3 of all 
HBV infections, but more than 50% of all HCC cases. Despite 
major efforts to improve diagnosis and treatment, HCC still 
carries  an  extremely  poor  prognosis,  leading  to  600,000 
deaths globally each year (2). The median survival for HBV-
related HCC is less than 16 months, and the five-year survival 
rate ranges from 15-26% (9). The most effective treatments for 
HCC are surgical resection, liver transplantation, and radiof-
requency ablation (16). However, these treatments are avail-
able to only a low percentage of patients, recurrence rates 
are still high. Thus, it is important to understand the mecha-
nisms  of  HBV-induced  hepatocarcinogenesis  and  identify 
the predictors for HCC. Early identification of HBV-infected 
individuals who will eventually develop HCC is important 
for developing effective prevention methods, active surveil-
lance, and novel treatment options. In this review, we mainly 
focus on the HBV properties and their associations with the 
risk of HCC.
Viral replication and the association with HCC
HBV belongs to hepadnaviridae, a family of enveloped vi-
ruses with an incomplete double-stranded DNA genome of 
3.2 kb (Figure 1). The HBV genome contains four overlapping 
open reading frames, which encode the three hepatitis B sur-
face antigens (HBsAg) (encoded by the S gene, preS2/S genes 
and preS1/preS2/S genes), hepatitis B e antigen (HBeAg) and 
hepatitis B core antigen (HBcAg) (encoded by preC/C genes), 
viral polymerase (encoded by P genes), and a multifunction-
al nonstructural protein called X (encoded by the X gene). 
The preS region (nucleotides [nt] 2854-155), which consists of 
preS1 and preS2, overlaps a region encoding the polymerase 
gene. The enhance II (Enh II, nt.1636-nt.1744) and basal core 
promoter (BCP, nt.1751-nt.1769) regions overlap with the X 
gene (nt.1374-nt.1835). The overlapping structure of the cod-
ing regions makes the utility of the HBV genome more than 
150%. The BCP, which is regulated by Enh II and to some ex-
tent by Enh I, controls the transcription of precore mRNA 
and core mRNA and viral generation (17). The precore region 
encodes the precore protein, which is processed in the en-
doplasmic  reticulum  to  produce  secreted  HBeAg.  HBeAg 
is clinically used as an indicator of active viral replication 
and has, along with viral load, been associated with an in-
creased risk of HCC in a prospective study (18). A HBV DNA 
load higher than 1×10
4 copies/mL is an important predictor 
of the development of HCC in asymptomatic HBsAg carriers 
(ASCs),  independent  of  HBeAg,  alanine  aminotransferase 
(ALT) level, or cirrhosis (19). Viral load is associated with an 
increased risk of cirrhosis in HBeAg-negative HBV-infected 
individuals (20). The interval from diagnosis of cirrhosis to 
development of HCC among high–HBV DNA individuals is 
much shorter than that among persistently low–HBV DNA 
individuals (21). This evidence indicates that high viral load 
is a reliable marker of high risk of HCC in HBV-infected indi-
viduals. High viral load and active hepatitis can also be found 
in some HBV carriers who have already developed anti-HBe 
antibody. There are two well-defined mutations reported to 
be associated with HBeAg expression. One is a G-to-A muta-
tion at nt.1896 (G1896A) in the precore region, which induces 
a stop codon and cessation of HBeAg expression. Another is 
the double mutation A1762T/G1764A in the BCP region, which 
decreases HBeAg production by 70% through suppressing 
the transcription of precore mRNA (22, 23). Thus, HBeAg sta-
tus and anti-HBe status are less reliable markers than HBV 
DNA level for viral replication or the risk of HCC. High viral 
load is also an important risk factor for post-treatment re-
currence of HCC, irrespective of the pattern of recurrence 
(24). Large prospective studies are needed to see if antiviral 
therapy can reduce or postpone the occurrence of HCC or 
improve the tumor-free survival rate after curative resection 
in HBV-related HCC patients with high viral load.
Figure 1. Diagram for HBV genomic structure
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HBV genotypes and their associations with HCC
According to a sequence divergence greater than 8% in the 
entire HBV genome, 8 genotypes (A-H) have been identified 
(25), and two additional genotypes, provisionally designated 
as genotype I and genotype J, have been isolated in Vietnam 
and Japan, respectively (26, 27). HBV genotypes can be further 
divided into subgenotypes if the divergence in the whole 
genome is between 4-8%. HBV genotypes and subgenotypes 
have distinct geographical distributions (Figure 2) (25, 28-30). 
Genotype A is endemic in southern and western parts of Afri-
ca (subgenotypes A1, A3-A5) and western and northern parts 
of Europe (A2). Genotypes B and C are endemic in eastern 
and southeastern Asia. Genotype D is endemic in the Medi-
terranean area, the Middle East, and other parts of western 
Asia. Genotype E is restricted to West Africa and genotype F 
is frequent in Central America. Genotypes G and H have been 
found in South America. Our recent community-based study 
found that in Mainland China subgenotypes B2 (27.3%), C1 
(10.7%), and C2 (58.0%) are predominant (31). We found that 
the compositions of subgenotypes B2, C1, and infection with 
multiple HBV genotypes (genotype mixture) increase from 
the north to central south of China, and is associated with 
an increasing prevalence of HBsAg. The distribution of HBV 
genotypes and subgenotypes may help in determining dis-
ease burden. HBV genotypes and subgenotypes have been 
shown to differ with regard to HBeAg seroconversion, clini-
cal outcomes, prognosis, and antiviral responses. However, 
the role of HBV genotypes in HCC risk is still controversial 
(32).  Sample  size,  predominance  of  one  genotype  in  one 
population, study design and other confounding factors are 
issues for both positive and negative findings. In Mainland 
China, seropositive HBeAg is more common in subgenotype 
B2–infected individuals younger than 35 years, rather than 
in those older than 35 years, as compared with individuals 
infected with subgenotype C2. The same is true for HBV DNA 
level between individuals infected with subgenotype B2 and 
subgenotypes C1/C2 (31). Genotypes A, B, D, and F are associ-
ated with earlier spontaneous HBeAg seroconversion than 
genotype  C,  and  HBeAg  seroconversion  confers  favorable 
long-term  outcomes  (31,  33-35).  We  have  recently  demon-
strated that subgenotype B2 is more likely to be associated 
with acute HBV, while genotype C (subgenotype C2) is more 
likely to cause CHB than subgenotype B2 following an acute 
infection course (36). Studies in East Asia have demonstrated 
that genotype C CHB is more likely than genotype B to cause 
cirrhosis and HCC (37-40). Genotype C CHB is associated with 
an increased risk of HCC in cirrhotic patients over 50 years, 
whereas infection with genotype B (B2) has been found to 
be associated with the development of HCC in non-cirrhotic 
young patients and relapse of HCC after surgical treatment 
(40-42). High viral load and genotype C have an additive role 
in increasing the risk of HCC (40). Although subgenotypes 
C1 and C2 are associated with an increased risk of HCC, only 
subgenotype C2 is independently associated with HCC (43). 
Genotype mixture, which is frequently found using multi-
plex PCR method (44), is often associated with higher viral 
load and a more severe course of liver disease than genotype 
C alone (41). Subgenotype B1 (Bj) is restricted to Japan, while 
subgenotype B2 is endemic in most Asian areas. In Japan, the 
average age of HCC patients with subgenotype B1 is older 
than those with genotype C. Individuals with subgenotype 
B1 are frequently negative for HBeAg, have lower ALT levels, 
lower HCC occurrence, and a better prognosis (45). Genotype 
D has been associated with more severe liver disease than 
genotype A and may predict the occurrence of HCC in young 
patients (46). Different genotypes have shown different re-
sponses  to  interferon-alpha  (IFN-α)  treatment.  Compared 
to genotype C, genotype B has a higher rate of response to 
IFN-α treatment in HBeAg (+) CHB, and genotypes E, F, and 
H appear to be more sensitive to IFN-α than genotype G (47, 
48). Furthermore, genotype A is more sensitive to interferon 
than genotype D (49). Taken together, subgenotype B2 is as-
sociated with high viral load and HCC in young patients, 
with less frequency of cirrhosis, and is also associated with 
recurrence of HCC after surgery, possibly because of high vi-
ral load. Subgenotype C2 is more likely to be associated with 
persistent HBV infection following an acute course, and is as-
sociated with a high percentage of HCC in cirrhotic patients. 
IFN-α treatment is effective for patients with genotype A or 
B. There is rare evidence to show the association of other 
genotypes with the risk of HCC and response to treatment 
because a unique HBV genotype prevails in many areas. In-
ternational collaboration will help in elucidating the asso-
ciation of all HBV genotypes with the risk of HCC.
HBV mutations and their associations with HCC
Because  the  reverse  transcriptase  lacks  a  proofreading 
function, HBV exhibits a higher mutation rate than other 
DNA viruses. HBV mutants can show enhanced virulence, 
resistance to antiviral treatment, facilitated cell attachment 
or  alteration  of  epitopes  important  in  the  host  immune 
response (50). Mutations might be generated during HBV-
induced pathogenesis or antiviral treatment. Random viral 
mutation and directional selection by host immunity confer 
a distinctive mutation pattern of HBV in each liver disease. 
The HCC-associated mutations often occur in the Enh II/BCP/
precore and preS regions. Takahashi et al. (51) first identified 
HBV  mutations  through  the  comparative  analysis  of  full-
length HBV isolates (95% genotype C) from 40 HCC patients, 
and found that mutations in the preS2 region, A1762T, G1764A, 
and T1753C/A mutations in the BCP region, and G1613A and 
C1653T mutations in the Enh II region were more frequent 
in HCC patients. Numerous associations between HBV mu-
tations and risk of HCC have since been reported (52). The 
different HBV genotypes display distinct mutation patterns 
in the preS and Enh II/BCP/precore regions (31). To elucidate 
the association of HBV mutations with liver diseases, it is es-
Figure 2. Global distribution of HBV genotypes and subgenotypes. A-J, HBV geno-
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sential to clarify wild-type patterns in individuals without 
clinical liver diseases. However, previous studies have not 
shown the wild-type pattern of a given HBV genotype and 
the  genotype-specific  pattern  of  mutation  as  well.  At  the 
early stage of HBV infection, the wild-type form facilitates 
transmission from mother to child. Children whose moth-
ers carry mutants were mostly found to be infected with just 
the wild-type form of the same viruses, suggesting that the 
HCC-associated  mutants  (e.g.,  preS  deletion  mutants  and 
A1762T/G1764A mutants) may not transmit from mother to 
child (53, 54). In the HBeAg-positive period, viral load is high 
and immune selection is week. Immune selection may in-
crease during HBeAg seroconversion. HBeAg negativity has 
been associated with the presence of mutations in the BCP/
precore regions. The HBeAg-negative variant has a selective 
advantage over wild-type HBV within the livers of patients 
with CHB during an immune response (55). We have recently 
defined wild-type nucleotides at the hotspots (≥10% muta-
tion rate in the entire subjects) in the Enh II/BCP/precore or 
the preS region of genotypes B and C from HBeAg-positive 
“quasi-immunotolerant” ASC, and then evaluated the asso-
ciations of these mutations with HCC (56-59). This strategy 
has revealed a group of important mutations that are associ-
ated with the risk of HCC:
1) Mutations in the Enh II/BCP/precore region
We  and  others  have  found  that  C1653T,  T1753V,  A1762T/
G1764A,  T1674C/G,  and  T1766/A1768  are  associated  with  an 
increased risk of HCC (52, 56, 60). Frequencies of T1674C/G, 
C1653T, T1753V, and A1762T/ G1764A were more than 30% in 
patients  with  HCC,  which  make  clinical  examination  fea-
sible  and  clearly  discriminate  HBV-infected  patients  with 
and without HCC (56). A recent study showed that G1899A, 
C2002T, A2159G, A2189C, and G2203A/T in the precore/core 
gene are closely related to HCC (61). We have demonstrated 
that mutations at nt.1653, nt.1674, nt.1719, nt.1753, nt.1762, and 
nt.1846 in genotype C are associated with an increased risk 
of HCC compared with ASCs and patients with CHB. These 
associations are only found in HBeAg-negative individuals. 
Interestingly, C1673T, A1726C, A1727T, C1730G, T1768A, C1773T, 
and C1799G are associated with an increased risk of cirrhosis 
compared with patients with CHB, whereas these mutations 
are inversely associated with HCC compared with patients 
with cirrhosis (56). Recent prospective studies have demon-
strated that A1762T/G1764A occurs up to 10 years before the 
onset of HCC and is a useful predictor of HCC (62-64). Im-
portantly, of the HBV mutations independently associated 
with  an  increased  risk  of  HCC,  haplotypic  carriages  with 
two or more mutations, rather than a single one, are asso-
ciated with an increased risk of HCC (56). C1653T, T1674G/C, 
T1753V, A1762T, and G1764A mutations lead to amino acid (aa) 
transitions at aa94 (H-to-T), aa101 (S-to-A/P), aa127 (I-to-T/N/S), 
aa130  (K-to-M),  and  aa131  (V-to-I),  respectively.  In  addition, 
A1762T  introduces  a  translation  initiation  site  ATG  at  the 
C-terminal of X protein. HBV X mutations, especially the C-
terminal–deleted X protein, have been frequently found in 
HCC specimens (64-66). Further, the Enh II/BCP/precore is 
the regulatory region of HBV. The HCC-associated mutations 
lead to generation of HFH-2-, HNF-3b-, Skn-1-, Cdx-1-, cap-, and 
Oct-1-binding sites, which might represent novel virus–host 
interactions related to development, viral replication, proto-
oncogene activation, and carcinogenesis (57). Thus, HBV gen-
otype-associated mutations in the Enh II/BCP/precore region 
might be selected by HBV–host interaction during CHB and, 
in turn, promote hepatocarcinogenesis. It is also possible 
that the mutated X protein trans-activates host oncogenes 
responsible for the development of HCC or that trans-acti-
vators encoded by some oncogenes select the specific HBV 
mutations during HBV-induced hepatocarcinogenesis.
2) Mutation in the preS region
The preS1 and preS2 regions contain several epitopes for 
T and B cells, thus playing an essential role in the interac-
tion with host immune responses (17). The most common 
mutation in the preS is preS deletion (52), leading to an inef-
ficient immune response. The preS deletion also decreases 
the expression of surface proteins, resulting in intracellular 
accumulation of HBV envelope proteins and viral particles, 
formation of ground-glass hepatocytes, endoplasmic reticu-
lum stress, and oxidative DNA damage (17). These changes 
eventually  lead  to  hepatocarcinogenesis.  There  is  no  evi-
dence  that  the  preS  mutation  can  transmit  from  mother 
to child, so preS mutations are generated during the pro-
gression of CHB, especially in patients treated with IFN (30, 
53). The preS deletion has a higher prevalence in genotype 
C than genotype B, and is reported to be closely associated 
with  occult  HBV  infection  and  HCC  development  (67-69). 
Our recent studies have demonstrated that T53C, preS2 start 
codon  mutation,  preS1  deletion,  and  novel  mutations  in-
cluding C2964A, A2962G, C3116T, and C7A are associated with 
an increased risk of HCC, while a novel mutation C105T in 
preS2 region is inversely associated with the risk of HCC (57, 
58, 59). The frequencies of combined preS mutations such 
as 2964C-3116T-preS2 start codon wild-type-7A, 2964C-3116T-7-
A-76C, and 2964A-3116T-7C-76A/T are higher in patients with 
HCC, whereas the haplotypic carriages with a single muta-
tion and other three wildtypes are inversely associated with 
HCC (58). C2875A, G2946C, G2950A, G2951A, A2962G, C2964A, 
T3066A, T3069G, C3116T, A3120T, C7A, and T53C are inversely 
associated with the risk of cirrhosis, whereas these muta-
tions are associated with an increased risk of HCC (56), indi-
cating HCC and cirrhosis might have distinctive processes of 
immune selection for mutations.
HBV properties for the prediction of HCC
As mentioned above, evidence from case-control studies 
and cohort studies have demonstrated that high viral load 
(>10
4 copies/mL), genotype C (especially subgenotype C2), 
and mutations (especially in the Enh II/BCP/precore and the 
preS regions) are independently associated with increased 
risks of HCC, indicating that these viral properties can be 
used  for  the  prediction  of  HCC  in  HBV-infected  individu-
als. A1762T/G1764A can be detected up to 10 years before the 
onset of HCC, and mutations such as the preS deletion and 
the complex mutations in the BCP regions frequently occur 
from months to years after the detection of A1762T/G1764A 
(60).  The  frequencies  of  the  preS  deletion,  C1653T,  T1753V, 
and A1762T/G1764A mutations consecutively increased dur-
ing the progression from ASCs to HCC, indicating that these 
mutations accumulate before the diagnosis of HCC (52). As 
different mutations have distinctive power to indicate the HBV properties and hepatocarcinogenesis 90 Zhang Q et al.
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